The ACCP and NHLBI National Conference on Antithrombotic Therapy aims to provide consensus on the appropriate use of antithrombotic therapy across various cardiovascular disorders.
Answers are grounded in this paper and cite their sources.
Supports antithrombotic use in VTE, unstable angina, bypass shunt thrombosis, and TIA; confirms RCT efficacy while leaving other indications open.
INTRODUCTION Antithrombotic therapy has been recommended at one time or another for nearly every A cardiovascular disorder that is seen in daily practice. In determining which patients should be treated, the clinician faces a most difficult task because the information for the efficacy of antithrombotic therapy for many disorders is incomplete and the recommendation to use antithrombotic therapy has been based on case series or clinical judgment. In recent years, a number of randomized studies have been performed, which have provided definitive information on the value of antithrombotic therapy in a number of cardiovascular disorders including: the prevention and treatment of venous thromboembolism; treatment of unstable angina; prevention of shunt thrombosis after aortocoronary bypass surgery, and treatment of transient cerebral ischemia. However, information is incomplete for many common disorders and there are few important areas of medicine in which the lack of consensus on appropriate management is so evident. To
No takes yet. Share an insight, caveat, or question.
James E. Dalen (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: